Welcome to Idorsia

Idorsia announces
financial results for the
first nine months
of 2021

Our key assets have
the potential to
transform treatment in
the target indications...

Our 2020 report
consists of four
books

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

13 Dec 2021	Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study
01 Nov 2021	Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus
27 Oct 2021	Johnson & Johnson partially converts its convertible loan

Event	When
Full-Year 2021 Financial Results reporting*	February 8, 2022
Annual General Meeting of Shareholders	April 14, 2022
First-Quarter 2022 Financial Results reporting*	April 26, 2022
Half-Year 2022 Financial Results reporting*	July 26, 2022

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:19:56 CET

18.64 CHF

0.00 (0.00 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland